GH Research is a clinical-stage biopharmaceutical company developing mebufotenin (5-MeO-DMT) product candidates for hard-to-treat depression and related psychiatric conditions. Its lead program, GH001, is a pulmonary inhalation formulation studied in treatment-resistant depression, with additional work in bipolar II depression and postpartum depression. The company aims for fast-onset, durable antidepressant effects with clinic-administered dosing rather than chronic daily oral therapy.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -9.3 | — |
| Q3 2025 | 0 | — | -14 | — |
| Q4 2025 | 0 | — | -14.1 | — |
| Q1 2026 | 0 | — | -19 | — |
| Q2 2026 | 0 | — | -15.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: American Superconductor Corporation (AMSC), The Goodyear Tire & Rubber Company (GT), Trupanion, Inc. (TRUP), First Tracks Biotherapeutics, Inc. (TRAX), Capital Clean Energy Carriers Corp. (CCEC), Nektar Therapeutics (NKTR)